Endogenous ligands for kappa-opiate receptors

Area of Science:

• Pharmacology
• Neuroscience
• Molecular Biology

Background:

• Opioid receptors play a crucial role in regulating physiological processes.
• Understanding opioid receptor subtypes and their ligands is essential for developing targeted therapeutics.
• The mouse vas deferens is a well-established model for studying opioid receptor pharmacology.

Purpose of the Study:

• To investigate the receptor preferences of various opioid peptides in the mouse vas deferens.
• To determine the kappa- and delta-opioid receptor activities of alpha-neoendorphin, dynorphin, and its fragments.
• To explore the potential kappa-agonistic properties of met-enkephalin[Arg6,Gly7,Leu8].

Main Methods:

• Tolerance and cross-tolerance studies were conducted using superfusion techniques.
• Preparations were rendered tolerant in situ with kappa-receptor agonists (dynorphin, alpha-neoendorphin).
• In vitro experiments maintained tolerance using the respective peptides.

Main Results:

• Alpha-neoendorphin and dynorphin (fragments 1-13, 1-11) demonstrated significant kappa-agonistic activity.
• As dynorphin fragments shortened, kappa-receptor activity decreased, and delta-receptor activity became more apparent.
• Met-enkephalin[Arg6,Gly7,Leu8] exhibited considerable kappa-agonistic properties under experimental conditions.

Conclusions:

• Both alpha-neoendorphin and dynorphin, along with shorter fragments, interact with kappa-opioid receptors in the mouse vas deferens.
• The observed shift from kappa to delta receptor activity with dynorphin shortening suggests differential receptor binding.
• Met-enkephalin[Arg6,Gly7,Leu8] may also interact with kappa and potentially delta receptors, indicating broader opioid receptor engagement.